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Colorectal Cancer 
• 3rd leading cause of cancer and 2nd leading cause of 
cancer related deaths in the United States1 
• African Americans have higher rates of recurrence1 
• Guanylyl cyclase C (GCC) is a protein that is over 
expressed by metastatic colorectal tumors 
• Cancer clinical trials 2, 3 
– Participation is 3-5% 
– Recruitment (communication challenges) 
– Lower rates in African Americans 
1. Center for Disease Control, 2012    
2. Cox & Mcgarry, European Journal of Cancer Care, 2003  
3. National Cancer Institute Cancer Bulletin, 2009. 
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Health Services Research 
• Addresses patient access to health care and health 
care services as well as patient outcomes and 
effectiveness of health care 
• Addressing racial barriers in participating in cancer 
vaccine trials 
• Develop a decision support intervention to improve 
informed participation 
   Identify factors that may influence trial participation 
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Theoretical Framework4 
Figure 1. The PHM and AHP in Mediated Decision Support
- Perceived Susceptibility
- Salience and Coherence
- Worries and Concerns
- Response Efficacy
- Social Support
- Decision Stage
Preference
Clarification
Likelihood
Assessment
Planning
Decision Action
Experience
Representations Decision Making, Planning, and Performance
 
* PHM = Preventive Health Model, AHP = Analytic Hierarchy Process 
4. Myers (2005) Health Psychology 
* 
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Phases of The CCV Study 
Phase III 
In-Person Decision 
Counseling 
Phase II 
Pre-test and Feasibility 
Assessment 
Phase I 
Materials & Methods 
Development 
 
• Conduct literature 
review 
 
• Develop and pretest 
trial informational 
booklet 
 
• Adapt web-based 
decision counseling 
program 
 
• Prepare questionnaire 
for Phase 2 survey 
 
• Pilot test informational 
booklet 
 
• Administer Survey 
 Measure 
intention to 
participate in trial 
 
 Identify patient 
factors 
associated with 
intention to 
participate in trial  
 
• Identify patients 
interested in trial 
participation 
 Determine 
preference for 
trial participation 
 
• Refer interested 
patients to study 
coordinator for 
enrollment 
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Phase I: Conclusions 
• Perceived effectiveness of the informational booklet 
varied by age 
– Older patients found the booklet more challenging 
• Modifications to the booklet 
– Large print 
– Subheadings 
– Reducing reading level from 11th grade to an 8th grade level 
– Additional information 
• clarify side effects and safety 
• participation requirements 
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Informational Trial Booklet 
• Developed and pre-tested the Informational Booklet 
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Phase II 
• Began my research during the middle of phase II 
– Recruitment at 21 patients (19 Whites and 2 Blacks) 
– Goal is 25 Blacks and 25 Whites 
• Literature review 
• Data entry 
• Preliminary Analyses 
 
   Identify factors that may influence trial participation 
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Literature Review 
• Search databases were RefWorks, Scopus, and 
PubMed 
• Annotated 42 articles 
• Identified factors that influence trial participation: 
– Decision-Making Process (9) 
– Participant – provider communication (12) 
– Decision Aids (11) 
– Recruitment Strategies (10) 
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Literature Review 
• Decision Making Process 
– Shared decision making is ideal for increasing trial participation 
• Patient – Provider Communication 
– Important to ensure participants have complete understanding of 
the research study 
• Test/feedback mechanisms 
• Recruitment Strategies 
– Specific to culture and socio-demographics will increase trial 
participation 
• Decision Aids 
– Enhanced informed consent, audiovisuals, and in-person 
interactions seem to influence trial parcipation 
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Phase II 
• Independent Variables 
– Background Characteristics 
– Knowledge about the CCV Study 
– Thoughts about joining the CCV Study 
– Perceptions about Religion and Health 
– Perceptions about Health Care Research 
– Thoughts about the CCV Informational Booklet 
• Dependent Variable 
– Intention to join the CCV Study if it were available today 
(hypothetical scenario) 
• Goal of recruitment 
– 25 Whites and 25 Blacks 
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Intention to Join CCV Study 
Introduction 
 Colon cancer can come back (recurrence) among some people who have had early 
 (Stage I or II) colon cancer. Currently, there is no known treatment that prevents 
 colon cancer recurrence. This problem is the focus of a study, the Colon Cancer 
 Vaccine Study 
 
 In the Colon Cancer Vaccine Study, work is now underway to develop a new vaccine 
 that may help to prevent colon cancer recurrence. When the vaccine is ready, it 
 must be evaluated to make sure it is safe and is effective in activating the body’s 
 defense (immune system). At that time, we  will ask eligible patients to join a 
 research study intended to evaluate the vaccine.  
 
Summary of Steps in the Colon Cancer Vaccine Study 
• Sign a consent form, complete blood studies, provide their medical history 
information, and have a physical exam. 
• Visit the clinic, receive the vaccine injection in the upper arm, and remain for at least 
30 minutes to make sure there are no reactions to the vaccine. (Mild flu-like 
symptoms are an example of a potential side effect of the vaccine) 
• Receive follow up telephone calls to assess well-being 
• Visit the clinic at one, three, and six months to evaluate response to the vaccine and 
have blood studies.  
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Phase II: Participant Accrual 
Figure 2: Participant Accrual for Phase II 
Center of Excellence  
In 
Cancer  
Immunotherapy 
Phase II: Participant Characteristics 
Characteristic      N(%)   
 
Study Site  Thomas Jefferson University   14 (67)  
  University of Pittsburgh     7 (33) 
  Fox Chase Cancer Center   --------- 
 
Age           ≤ 65     11   (52) 
                  > 65     10   (48) 
 
Gender  Male       9   (43) 
  Female     12   (57) 
 
Race  White     19   (90) 
  Black         2   (10) 
 
Marital Status Married      11  (52)   
  Not Married     10  (48)  
 
Education  ≤ High School       8  (38) 
  > High School     13  (62) 
 
 
 
Table 1: Summary of Participant Characteristics for Phase II, n=21 participants 
Note: Recruitment is not complete for Phase II 
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Intention to Join CCV Study 
If the vaccine were available today and you were asked 
to join the Colon Cancer Vaccine Study, what do you 
think you would do? 
 
 I would join 
 
 I am unsure what I would do 
 
 I would not join 
6 
11 
4 
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Background Characteristics of Participants by 
Joining the CCV Study if the Vaccine Were 
Available Today 
Fisher’s Exact Test, n=21 
Table 2: Summary of Background Characteristics of Participants by Joining the CCV Study 
              Would Not Join/Unsure     Would Join      
Characteristics                 n   (%)           n   (%)                     P-Value  
 
Age  ≤ 65                  10   (90.91)         1   (  9.09)     0.0635 
  > 65          5   (50.00)        5   (50.00)  
 
Sex  Male         5   (55.56)        4   (44.44)     0.3310 
  Female                         10   (83.33)        2   (16.67)  
 
Race  White            14   (73.68)         5   (26.32)     0.5000 
  Black                           1   (50.00)        1   (50.00) 
 
Marital Status              Married                           8   (72.73)        3   (27.27)         1.0000       
  Not Married                         7   (70.00)                    3   (30.00)          
 
Education   ≤ High School          5   (62.50)        3   (37.50)      0.6311 
                     > High School                   10   (76.92)        3   (23.08) 
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Summary of Survey Responses: Joining the 
CCV Study if Vaccine Were Available Today by 
Thoughts about Joining the CCV Study 
                               Would Not Join/Unsure     Would Join      
Survey Items                 n   (%)           n   (%)                     P-Value  
 
Important thing for            Disagree       10   (66.67)         0   (  0.00)     0.0124 
me to do                                Agree           5   (33.33)        6   (100.00)  
 
Could help protect  Disagree           7   (46.67)        0   (  0.00)     0.0609 
my health                       Agree        8    (53.33)        6   (100.00)  
 
Could help prevent      Disagree         10   (66.67)         1   (16.67)     0.0635  
a recurrence                   Agree         5   (33.33)        5   (83.33) 
 
Family thinks I              Disagree        13   (86.67)        2   (33.33)         0.0307       
should join                     Agree         2   (13.33)                    4   (66.67)          
 
My doctor thinks  Disagree          13   (86.67)        2   (33.33)      0.0307 
I should join  Agree            2   (13.33)        4   (66.67) 
 
   
Fisher’s Exact Test, n=21 
Table 3: Summary of Joining the CCV Study  If Vaccine Were Available Today  by Thoughts about Joining the CCV Study 
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Phase II: Implications 
• Representations of Theoretical Model 
– Salience and Coherence 
• Those patients who agreed that joining is important and want to join, may be 
more likely to follow through with the requirements of participation 
• Time and effort of research staff is not wasted 
– Response Efficacy 
• Protect my health (67%) 
• Prevent a recurrence (48%) 
• False hope or false reassurance (therapeutic fallacy) 
– Social Influences (i.e. doctor and/or family) 
• 13 participants (61%) disagreed with believing their family thinks they should 
join and 13 participants (61%) disagreed with believing their doctor thinks they 
should join 
• Provide more information to the providers and/or encourage participants to talk 
with family members about the vaccine and invite them to read the 
informational booklet and/or in the future attend the in-person decision 
counseling session 
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• Age has a tendency to be associated with intention to 
join the CCV study 
• Attitudinal Factors 
– Important thing for me to do 
– Could help protect my health (marginally significant) 
– Could help prevent a recurrence (marginally significant) 
– Family thinks I should join 
– Doctor thinks I should join 
• Preliminary analyses, all these factors may change! 
   Identify factors that may influence trial participation 
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Future of Health Services Research 
• Phase III 
– Identify patients interested in trial participation 
– Determine preference for trial participation 
• Combine informational booklet and web-based decision counseling 
• Refer interested patients to study coordinator for vaccine trial 
enrollment 
 
   Would Not Join Unsure     Would Join      
Survey Item           n   (%)  n   (%)                 n   (%)              
Would you like to 
be notified when                 No          2    (  9.52)               0    (  0.00)          0   (  0.00) 
the vaccine trial                  Yes         2    (  9.52)              11   (52.38)          6   (28.57) 
is ready to enroll?  
Table 4: Summary of participants that would like to be notified when the vaccine trial is ready to enroll by 
participants who would join if vaccine were available today 
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Lessons Learned 
• Important to participate in clinical research 
– The Immortal Cells of Henrietta Lacks” by Rebecca Skloot 
– Understand the trial 
– Make an informed decision 
• Importance of a statistician 
• The value of reading literature 
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